Tashkin, D. P., Roth, M. D., Clements, P. J., Furst, D. E., Khanna, D., Kleerup, E. C., Goldin, J., Arriola, E., Volkmann, E. R., Kafaja, S., Silver, R., Steen, V., Strange, C., Wise, R., Wigley, F., Mayes, M., Riley, D. J., Hussain, S., Assassi, S., Hsu, V. M., Patel, B., Phillips, K., Martinez, F., Golden, J., Connolly, M. K., Varga, J., Dematte, J., Hinchcliff, M. E., Fischer, A., Swigris, J., Meehan, R., Theodore, A., Simms, R., Volkov, S., Schraufnagel, D. E., Scholand, M. B., Frech, T., Molitor, J. A., Highland, K., Read, C. A., Fritzler, M. J., Kim, G. H. J., Tseng, C., Elashoff, R. M., & , (2016). mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial. Lancet, 4(9), 708–719. http://access.bl.uk/ark:/81055/vdc_100035497111.0x000036